134 related articles for article (PubMed ID: 37914595)
21. Impact of adjuvant chemotherapy in completely resected stage IIIA non-small cell lung cancer.
Naim Younes R; Gross JL; Abrao FG; Rodrigues Pereira J
Minerva Chir; 2013 Apr; 68(2):169-74. PubMed ID: 23612230
[TBL] [Abstract][Full Text] [Related]
22. International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer.
Novello S; Torri V; Grohe C; Kurz S; Serke M; Wehler T; Meyer A; Ladage D; Geissler M; Colantonio I; Cauchi C; Stoelben E; Ceribelli A; Kropf-Sanchen C; Valmadre G; Borra G; Schena M; Morabito A; Santo A; Gregorc V; Chiari R; Reck M; Schmid-Bindert G; Folprecht G; Griesinger F; Follador A; Pedrazzoli P; Bearz A; Caffo O; Dickgreber NJ; Irtelli L; Wiest G; Monica V; Porcu L; Manegold C; Scagliotti GV
Ann Oncol; 2022 Jan; 33(1):57-66. PubMed ID: 34624497
[TBL] [Abstract][Full Text] [Related]
23. Randomized phase II study of daily versus alternate-day administrations of S-1 for the elderly patients with completely resected pathological stage IA (tumor diameter > 2 cm)-IIIA of non-small cell lung cancer: Setouchi Lung Cancer Group Study 1201.
Yamamoto H; Soh J; Okumura N; Suzuki H; Nakata M; Fujiwara T; Gemba K; Sano I; Fujinaga T; Kataoka M; Terazaki Y; Fujimoto N; Kataoka K; Kosaka S; Yamashita M; Inokawa H; Inoue M; Nakamura H; Yamashita Y; Hotta K; Yoshioka H; Morita S; Matsuo K; Sakamoto J; Date H; Toyooka S
PLoS One; 2023; 18(5):e0285273. PubMed ID: 37205678
[TBL] [Abstract][Full Text] [Related]
24. The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy.
Yang H; Wang K; Li S; Li Y; Yuan L
Pathol Oncol Res; 2021; 27():1609898. PubMed ID: 34447289
[No Abstract] [Full Text] [Related]
25. Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial.
Felip E; Altorki N; Zhou C; Vallières E; Martínez-Martí A; Rittmeyer A; Chella A; Reck M; Goloborodko O; Huang M; Belleli R; McNally V; Srivastava MK; Bennett E; Gitlitz BJ; Wakelee HA
Ann Oncol; 2023 Oct; 34(10):907-919. PubMed ID: 37467930
[TBL] [Abstract][Full Text] [Related]
26. Treatment Patterns and Health Resource Utilization Among Patients Diagnosed With Early Stage Resected Non-Small Cell Lung Cancer at US Community Oncology Practices.
Buck PO; Saverno KR; Miller PJ; Arondekar B; Walker MS
Clin Lung Cancer; 2015 Nov; 16(6):486-95. PubMed ID: 25681298
[TBL] [Abstract][Full Text] [Related]
27. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer.
Scagliotti GV; Fossati R; Torri V; Crinò L; Giaccone G; Silvano G; Martelli M; Clerici M; Cognetti F; Tonato M;
J Natl Cancer Inst; 2003 Oct; 95(19):1453-61. PubMed ID: 14519751
[TBL] [Abstract][Full Text] [Related]
28. Real-world adjuvant chemotherapy patterns and outcomes among elderly patients with resected early non-small-cell lung cancer in the USA.
Lee JM; Wang R; Johnson A; Ogale S; Kent M; Lee JS
Future Oncol; 2023 Jan; 19(1):37-47. PubMed ID: 36662515
[TBL] [Abstract][Full Text] [Related]
29. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline.
Pisters KM; Evans WK; Azzoli CG; Kris MG; Smith CA; Desch CE; Somerfield MR; Brouwers MC; Darling G; Ellis PM; Gaspar LE; Pass HI; Spigel DR; Strawn JR; Ung YC; Shepherd FA; ;
J Clin Oncol; 2007 Dec; 25(34):5506-18. PubMed ID: 17954710
[TBL] [Abstract][Full Text] [Related]
30. Postoperative adjuvant chemotherapy with PVM (Cisplatin + Vindesine + Mitomycin C) and UFT (Uracil + Tegaful) in resected stage I-II NSCLC (non-small cell lung cancer): a randomized clinical trial. West Japan Study Group for lung cancer surgery (WJSG).
Wada H; Miyahara R; Tanaka F; Hitomi S
Eur J Cardiothorac Surg; 1999 Apr; 15(4):438-43. PubMed ID: 10371118
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of adjuvant EGFR-TKIs for resected non-small cell lung cancer: a systematic review and meta-analysis based on randomized control trials.
Zhao P; Zhen H; Zhao H; Zhao L; Cao B
BMC Cancer; 2022 Mar; 22(1):328. PubMed ID: 35346117
[TBL] [Abstract][Full Text] [Related]
32. Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer.
Imaizumi M;
Lung Cancer; 2005 Jul; 49(1):85-94. PubMed ID: 15949594
[TBL] [Abstract][Full Text] [Related]
33. Epidermal growth factor receptor inhibitors as adjuvant treatment for patients with resected non-small cell lung cancer harboring EGFR mutation: a meta-analysis of randomized controlled clinical trials.
Zhao N; Wu ZP; Yang J; Feng WN; Yang SL; Luo Y; Ye J; Wang F; Zhang XW; Xiao Y; Wu LL; Gu WQ
World J Surg Oncol; 2023 Feb; 21(1):45. PubMed ID: 36782320
[TBL] [Abstract][Full Text] [Related]
34. Patterns and Predictors of Chemotherapy Use for Resected Non-Small Cell Lung Cancer.
Rajaram R; Paruch JL; Mohanty S; Holl JL; Bilimoria KY; Ko CY; Winchester DP; Patel JD; DeCamp MM
Ann Thorac Surg; 2016 Feb; 101(2):533-40. PubMed ID: 26507427
[TBL] [Abstract][Full Text] [Related]
35. A single-arm, phase 2 study of adjuvant chemotherapy with oral tegafur-uracil for pathologically lymphovascular invasion positive stage IA non-small cell lung cancer: LOGIK0602 study.
Tsuchiya T; Kamohara R; Muraoka M; Nagayasu T; Saeki S; Takenoyama M; Suzuki M; Inada K; Tokunaga S; Hayashi T; Urabe S; Koga T; Akamine S; Sugio K
BMC Cancer; 2020 Dec; 20(1):1192. PubMed ID: 33276755
[TBL] [Abstract][Full Text] [Related]
36. Postoperative radiotherapy with modern techniques does not improve survival for operable stage IIIA-N2 non-small cell lung cancer.
Predina J; Suliman R; Potter AL; Panda N; Diao K; Lanuti M; Muniappan A; Jeffrey Yang CF
J Thorac Cardiovasc Surg; 2023 May; 165(5):1696-1709.e4. PubMed ID: 36610886
[TBL] [Abstract][Full Text] [Related]
37. Postoperative Adjuvant Systemic Therapy in Completely Resected Non-Small-Cell Lung Cancer: A Systematic Review.
Bradbury P; Sivajohanathan D; Chan A; Kulkarni S; Ung Y; Ellis PM
Clin Lung Cancer; 2017 May; 18(3):259-273.e8. PubMed ID: 28162945
[TBL] [Abstract][Full Text] [Related]
38. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.
Douillard JY; Rosell R; De Lena M; Carpagnano F; Ramlau R; Gonzáles-Larriba JL; Grodzki T; Pereira JR; Le Groumellec A; Lorusso V; Clary C; Torres AJ; Dahabreh J; Souquet PJ; Astudillo J; Fournel P; Artal-Cortes A; Jassem J; Koubkova L; His P; Riggi M; Hurteloup P
Lancet Oncol; 2006 Sep; 7(9):719-27. PubMed ID: 16945766
[TBL] [Abstract][Full Text] [Related]
39. [Current status of postoperative adjuvant chemotherapy for completely resected non-small lung cancer].
Tsuboi M
Nihon Geka Gakkai Zasshi; 2014 May; 115(3):125-9. PubMed ID: 24946518
[TBL] [Abstract][Full Text] [Related]
40. Safety of adjuvant atezolizumab after pneumonectomy/bilobectomy in stage II-IIIA non-small cell lung cancer in the randomized phase III IMpower010 trial.
Lee JM; Vallières E; Ding B; Johnson A; Bhagwakar J; Rashidi S; Zhu QC; Gitlitz BJ; Weksler B; Costas K; Altorki N
J Thorac Cardiovasc Surg; 2023 Sep; 166(3):655-666.e7. PubMed ID: 36841745
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
